Psychopharmacology of adults with attention-deficit/hyperactivity disorder

Primary Psychiatry

Volumn 11, Issue 7, 2004, Pages 57-62

  Biederman, Joseph ^a,b   Spencer, Thomas J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; DESIPRAMINE; DEXAMPHETAMINE; GUANFACINE; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; OROS MPH; PEMOLINE; PLACEBO; VENLAFAXINE;

APPETITE DISORDER; ATTENTION DEFICIT DISORDER; AWARENESS; CONSTIPATION; DISEASE DURATION; DISEASE EXACERBATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPHORIA; ELDERLY CARE; ERECTILE DYSFUNCTION; GENERAL PRACTITIONER; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; NAUSEA; NERVOUSNESS; PATIENT COUNSELING; PATIENT MONITORING; POPULATION RISK; PSYCHOPHARMACOLOGY; REBOUND; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SUBSTANCE ABUSE; SUSTAINED RELEASE PREPARATION; TIC; WEIGHT REDUCTION; XEROSTOMIA;

EID: 3442887967     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1143-1146.
2. Bauermeister JJ, Canino G, Bird H. Epidemiology of disruptive behavior disorders. In: Greenhill L, ed. Child and Adolescent Psychiatric Clinics of North America. Philadelphia, PA: WB Saunders; 1994:177-194.
3. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: Implications for clinical diagnosis. J Atten Disord. 1996;1(3):147-161.
4. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002;5(4):189-202.
5. Spencer TJ, Biederman J, Wilens TE, Johnson M, Doyle R, Parekh S. Efficacy of MPH in adults with ADHD. Poster presented at: 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 22-27, 2002; San Francisco, CA.
6. Wender PH, Szajkowski L, Marchant B, Reimherr FW, Sanford E, Eden J. Long-term study of MPH in the treatment of ADHD in adults. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
7. Stein MA. Effectiveness of OROS methylphenidate in adolescents and adults with ADHD. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
8. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52(6):434-443.
9. Wender PH, Reimherr FW, Wood D, Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry. 1985;142(5):547-552.
10. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry. 1984;41(11):1059- 1063.
11. Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12):1453-1460.
12. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorders in adults. Clin Neuropharmacol. 1985;8(4):343-356.
13. Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990;31(5):416-425.
14. Iaboni F, Bouffard R, Minde K, Hechtman L. The efficacy of MPH in treating adults with ADHD. Poster presented at: 43rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 22-27, 1996; Philadelphia, PA.
15. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol. 2004;24(1):24-29.
16. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165(11):1475-1488.
17. Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/ hyperactivity disorder (ADHD). Clin Child Farm Psychol Rev. 2000;3(4):243-267.
18. Weisler RH, Chrisman AK, Wilens TE. Adderall XR dosed once-daily in adult patients with ADHD. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
19. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775-782.
20. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000;10(4):311-320.
21. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z. A randomised, double-blind, placebo-controlled trial of dexamphetamme in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 1999;33(4):494-502.
22. Horrigan JP, Barnhill LJ. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2000;61(6):414-417.
23. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223-228.
24. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder ('minimal brain dysfunction') in adults. A replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981;38(4):449-456.
25. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 1999;19(3):257-264.
26. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry. 1998;59(6):300-305.
27. Greenhill LL, Pliszka S, Dulcan MK, et al, for the American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 suppl):26S-49S.
28. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60(2):204-211.
29. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107(6):E105.
30. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):883-892.
31. Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42(4):424-433.
32. Wilens TE. Treatment of ADHD with once-daily OROS methylphenidate: results from a long-term open-label study. Poster presented at: 155th Annual Meeting of the American Psychiatric Association; May 18-22, 2002; Philadelphia, PA.
33. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110(2 pt 1):258-266,
34. Miller A, Lee S, Raina P, Klasen A, Zupanicic J, Olsen L. A Review of Therapies for Attention-Deficit/Hyperactivity Disorder. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessments; 1998.
35. Lord J, Paisley S. The Clinical and Cost Effectiveness of Methylphenidate for Hyperactivity in Childhood. London, UK: National Institute for Clinical Excellence; 2000.
36. Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention-Deficit/Hyperactivity Disorder (ADHD) in Childhood. London, UK: National Institute of Clinical Excellence; 2000.
37. Rapoport JL, Buschbaum MS, Zahn TP, Weingartner H, Ludlow C, Mikkelsen EJ. Dextroamphetamine: cognitive and behavioral effects in prepubertal boys. Science. 1978;199:560-563.
38. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36(5):589-596.
39. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995;52(6):444-455. Erratum in: Arch Gen Psychiatry. 1995;52(10):836.
40. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995;52(6):444-455. Erratum in: Arch Gen Psychiatry. 1995;52(10):836.
41. Gadow KD, Nolan E, Sprafkin J, Sverd J. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr. 1995;16(3):167-176.
42. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56(4):330-336.
43. Kurlan R. Methylphenidate to treat ADHD is not contraindicated in children with tics. Mov Disord. 2002;17(1):5-6.
44. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in non-human and human subjects: a review. Pharmacol Biochem Behav. 2001;68(3):611-627.
45. Jaffe SL. Failed attempts at intranasal abuse of Concerta. J Am Acad Child Adolesc Psychiatry. 2002;41(1):5.
46. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry. 2002;63(suppl 12):29-35.
47. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120.
48. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896-1901.
49. Spencer TJ. Efficacy and safety of atomoxetine in adults with ADHD. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
50. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784.
51. Biederman J, Heiligenstein JH, Faries DE, et al, for the Atomoxetine ADHD Study Group. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002;10(6):E75.
52. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(12):1140-1147.
53. Strattera [package insert]. Indianapolis, IN: Eli Lilly & Company; 2003.